(R)-2-<(tert-butyldimethylsilyl)oxy>-3-methylbutanoic acid | 119619-47-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (R)-2-<(tert-butyldimethylsilyl)oxy>-3-methylbutanoic acid
• 英文别名: (R)-2-(tert-butyldimethylsilyloxy)-3-methylbutanoic acid；(R)-2-[(tert-butyldimethylsilyl)oxy]-3-methylbutanoic acid；(2R)-2-[tert-butyl(dimethyl)silyl]oxy-3-methylbutanoic acid
• CAS: 119619-47-5
• 化学式: C₁₁H₂₄O₃Si
• 分子量: 232.395
• InChiKey: LPOQMJJLBZAHQJ-SECBINFHSA-N

物化性质

• 沸点：
  265.5±23.0 °C(Predicted)
• 密度：
  0.938±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.12
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (R)-2-<(tert-butyldimethylsilyl)oxy>-3-methylbutanoic acid 在 4-二甲氨基吡啶 、 氟化氢吡啶 、 三乙胺 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 77.9h， 生成 [(2R)-3-methyl-1-[(2R,3S)-3-[(2-methylpropan-2-yl)oxycarbonylamino]-4-oxo-4-phenylmethoxybutan-2-yl]oxy-1-oxobutan-2-yl] (2R,3S,4S)-4-(dibenzylamino)-3-hydroxy-2-methyl-5-pyridin-3-ylpentanoate
  参考文献：
  名称：

  Synthesis and Antimycobacterial Activity of 2,1′-Dihydropyridomycins

  摘要：

  Dihydropyridomycins 2 and 3, which lack the characteristic enol ester moiety of the potent antimycobacterial natural product pyridomycin (1), have been prepared from L-Thr, R- and S-hydroxy isovaleric acid, and 3-pyridinecarboxaldehyde. The 2R isomer 2 shows only 4-fold lower anti-Mtb activity than 1, indicating that the enol ester moiety in the natural product is not critical for its biological activity. This finding establishes 2 as a potent and more practical lead for anti-TB drug discovery.

  DOI：

  10.1021/ml300385q
• 作为产物：
  描述：

  1-(furan-2-yl)-2-methylpropan-1-ol 在 咪唑 、 臭氧 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 (R)-2-<(tert-butyldimethylsilyl)oxy>-3-methylbutanoic acid
  参考文献：
  名称：

  Preparation of optically active 2-furylcarbinols by kinetic resolution using the Sharpless reagent and their application in organic synthesis

  摘要：

  DOI：

  10.1021/jo00270a015

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS<br/>[FR] COMPOSÉS ET COMPOSITIONS HÉTÉROCYCLIQUES COMME INHIBITEURS DE C-KIT ET PDGFR KINASE
  申请人：IRM LLC

  公开号：WO2009105712A1

  公开（公告）日：2009-08-27

  The invention provides a novel class of compounds of Formula I: (I) pharmaceutical compositions comprising such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFRα and PDGFRβ kinases.

  这项发明提供了一类新型的化合物，其化学式为：(I) 制备包含这类化合物的药物组合物，用于治疗或预防与异常或失调的激酶活性相关的疾病或紊乱，特别是涉及c-kit、PDGFRα和PDGFRβ激酶异常活化的疾病或紊乱。
• PYRIDOMYCIN BASED COMPOUNDS EXHIBITING AN ANTITUBERCULAR ACTIVITY
  申请人：ETH Zurich

  公开号：US20150246907A1

  公开（公告）日：2015-09-03

  Formula (1), X 1 represents O or NR 6 , X 2 represents O or NR 6 , X 3 represents O or NR 1 , R 1 represents H or C 1 to C 3 alkyl, R 2 represents H, or linear or branched C 1 -C 8 alkyl optionally including one or more heteroatoms, cyclopropyl, cyclobutyl, cyclohexyl or oxetanyl or amino acid side chain or protected amino acid side chain, or R 1 and R 2 may form together a saturated, partly saturated or unsaturated 5 or 6 membered ring system, optionally substituted, R 3 represents H, cyclopentyl, cyclohexyl, aryl or hydroxyaryl, aryl or hydroxyaryl being optionally substituted by fluorine, or linear or branched C 1 to C 8 alkyl optionally including a hetero atom, R 4 represents phenyl or 5- or 6-membered heterocycles including one or more nitrogen or oxygen atoms optionally substituted with 1 to 4, respectively 5 fluorine atoms, and R 6 represents H, or linear or branched alkyl chain having 1 to 3 carbon atoms.

  公式（1），X1代表O或NR6，X2代表O或NR6，X3代表O或NR1，R1代表H或C1到C3烷基，R2代表H，或线性或支链的C1-C8烷基，可选地包括一个或多个杂原子，环丙基，环丁基，环己基或氧环丙基或氨基酸侧链或保护的氨基酸侧链，或R1和R2可以形成一个饱和的，部分饱和的或不饱和的5或6成员环系统，可选地取代，R3代表H，环戊基，环己基，芳基或羟基芳基，芳基或羟基芳基可选地被氟取代，或线性或支链的C1到C8烷基，可选地包括一个杂原子，R4代表苯或包括一个或多个氮或氧原子的5-或6成员杂环，可选地用1到4，分别用5氟原子取代，R6代表H，或具有1到3个碳原子的线性或支链烷基链。
• HETEROCYCLIC COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS
  申请人：Chianelli Donatella

  公开号：US20110183997A1

  公开（公告）日：2011-07-28

  The invention provides a novel class of compounds of Formula I: (I) pharmaceutical compositions comprising such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFRα and PDGFRβ kinases.

  本发明提供了一类新型的化合物，其化学式为I：(I)，以及包含这些化合物的药物组合物，用于治疗或预防与异常或失调的激酶活性相关的疾病或障碍，尤其是涉及异常激活c-kit、PDGFRα和PDGFRβ激酶的疾病或障碍。
• Heterocyclic compounds and compositions as c-kit and PDGFR kinase inhibitors
  申请人：IRM LLC

  公开号：US08278452B2

  公开（公告）日：2012-10-02

  The invention provides a novel class of compounds of Formula I: (I) pharmaceutical compositions comprising such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFRα and PDGFRβ kinases.

  本发明提供了一种新型的I式化合物类：(I)，以及包含这些化合物的制药组合物，用于治疗或预防与异常或调节失常的激酶活性相关的疾病或障碍，尤其是涉及c-kit、PDGFRα和PDGFRβ激酶异常活化的疾病或障碍。
• KUSAKABE, MASATO;KITANO, YASUNORI;KOBAYASHI, YUICHI;SATO, FUMIE, J. ORG. CHEM., 54,(1989) N, C. 2085-2091
  作者：KUSAKABE, MASATO、KITANO, YASUNORI、KOBAYASHI, YUICHI、SATO, FUMIE

  DOI：——

  日期：——